Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

248
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

6.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Group Therapy01:26

Group Therapy

460
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
460
Behavior Therapy01:22

Behavior Therapy

732
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
732

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2021
Same author

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition.

NPJ precision oncology·2021
Same author

Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2021
Same author

Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease.

Scientific reports·2021
Same author

Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.

JHEP reports : innovation in hepatology·2021
Same author

Incidence of spontaneous bacterial peritonitis among asymptomatic cirrhosis patients undergoing outpatient paracentesis: a systematic review and meta-analysis.

European journal of gastroenterology & hepatology·2021

Related Experiment Video

Updated: Feb 11, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K

Future therapy of hepatitis C.

John G McHutchison1, Keyur Patel

  • 1Duke Clinical Research Institute, Durham, NC 27715, USA. mchut001@mc.duke.edu

Hepatology (Baltimore, Md.)
|October 31, 2002
PubMed
Summary

New hepatitis C virus (HCV) therapies show promise for improved effectiveness and tolerability. Further research is needed to establish the safety and efficacy of these novel treatments before widespread clinical adoption.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Current hepatitis C virus (HCV) treatments are effective in only 50% of patients, often causing side effects and high costs.
  • Ideal HCV therapies require high efficacy, oral bioavailability, minimal side effects, cost-effectiveness, and broad patient suitability.

Purpose of the Study:

  • To review recent advances in understanding HCV replication and the development of novel therapeutic strategies.
  • To discuss ongoing research into new antivirals, immunomodulators, and antifibrotic agents for HCV treatment.

Main Methods:

  • Review of current literature on hepatitis C virus (HCV) treatment landscape.
  • Analysis of emerging therapeutic compounds in preclinical and early-phase human trials.
  • Discussion of challenges, including the lack of a suitable small animal model for HCV infection.

More Related Videos

A Preclinical Murine Model of Hepatic Metastases
06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

30.5K
Murine Bioluminescent Hepatic Tumour Model
05:23

Murine Bioluminescent Hepatic Tumour Model

Published on: July 17, 2010

17.8K

Related Experiment Videos

Last Updated: Feb 11, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K
A Preclinical Murine Model of Hepatic Metastases
06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

30.5K
Murine Bioluminescent Hepatic Tumour Model
05:23

Murine Bioluminescent Hepatic Tumour Model

Published on: July 17, 2010

17.8K

Main Results:

  • Advances in understanding HCV replication and viral protein structures facilitate novel drug development.
  • Emerging therapies include direct-acting antivirals targeting viral enzymes, translation inhibitors, and immunomodulators.
  • Antifibrotic agents are being developed for patients with non-eradicable HCV RNA.

Conclusions:

  • Novel therapies represent an exciting advancement in HCV treatment, offering potential for improved outcomes.
  • Further clinical evaluation is crucial to establish the safety and efficacy of these emerging treatments.
  • Widespread clinical availability of most new therapies is not expected within the next 3-5 years.